RENT.COM.AU LIMITED — Board/Management Information 2005

Jun 8, 2005

COMPANY ANNOUNCEMENT

Appointment of New Director

Melbourne, Australia. 9th June 2005. Select Vaccines Limited (ASX:SLT) is pleased to announce the appointment of Mr. Robin Beaumont as a Non-Executive Director of the Company. Mr. Beaumont brings a strong set of skills, expertise and experience to the Board. These have been developed in the biotechnology and other commercial sectors.

Mr. Beaumont has been a Director of Gropep Limited (ASX:GRO) since 1999 and is also Chairman of Primegro Limited, an un-listed animal biotechnology company. Both of these companies are profitable. In addition, he is a Director of Evogenix Limited, a company developing novel antibody-based therapeutics and is Chairman of the Cooperative Research Centre for Diagnostics.

Commenting on the appointment, Mr. Cooper, Executive Chairman of Select Vaccines, said; "I am delighted that we have been able to attract someone of Robin's calibre to the Board of Select Vaccines. I believe he will make a significant contribution to the Company, particularly as a result of his experience in assisting developing companies reach commercial success."

ENDS

About Select Vaccines Limited

Select Vaccines is in partnership with Melbourne's Burnet Institute to develop and commercialise esearch outcomes in the areas of diagnosis, vaccination and therapy for infectious diseases caused by viruses. The Burnet Institute, established in 1986, is Australia's leading research organisation in the field of infectious diseases caused by viruses and other agents. Select has two project companies. Hepgenics Pty Ltd and Picoral Pty Ltd, which undertake different areas of research and development. Hepgenics is commercialising highly promising R&D projects in diagnostics and vaccines developed by researchers at the Burnet Institute. Picoral's research interests cover the development of therapeutic products with actions against the Picomavirus family, responsible for a range of illnesses that includes the common cold, meningitis and encephalitis.

Further information:

Mr. Jeremy Cooper, Executive Chairman (03) 98248166 Dr. Martin Soust, Managing Director (03) 8508 8250